ACADIA Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- ACADIA Pharmaceuticals's estimated annual revenue is currently $474.4M per year.
- ACADIA Pharmaceuticals received $316.2M in venture funding in November 2018.
- ACADIA Pharmaceuticals's estimated revenue per employee is $688,520
- ACADIA Pharmaceuticals's total funding is $811.7M.
- ACADIA Pharmaceuticals's current valuation is $3.7B. (January 2022)
Employee Data
- ACADIA Pharmaceuticals has 689 Employees.
- ACADIA Pharmaceuticals grew their employee count by 1% last year.
ACADIA Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Accounting Officer | Reveal Email/Phone |
4 | VP Patient Advocacy and Industry Relations | Reveal Email/Phone |
5 | VP Clinical Development | Reveal Email/Phone |
6 | SVP Strategy and Planning R&D | Reveal Email/Phone |
7 | VP, General Manager Long-term Care | Reveal Email/Phone |
8 | SVP Marketing & Commercial Strategy | Reveal Email/Phone |
9 | VP, Neuroscience Sales | Reveal Email/Phone |
10 | VP, Market Access & Patient Services | Reveal Email/Phone |
ACADIA Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (CNS) disorders. All of ACADIA's product candidates emanate from internal discoveries. We believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. ACADIA's history is rooted in science and strong leadership in CNS research. Our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. Since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. ACADIA is headquartered in San Diego. The city represents the second largest biotechnology industry cluster in the United States, home to over 400 companies, as well as the Salk Institute for Biological Studies and the Scripps Research Institute.
keywords:Biotechnology,Career / Job Search,Healthcare,Pharmaceuticals
$811.7M
Total Funding
689
Number of Employees
$474.4M
Revenue (est)
1%
Employee Growth %
$3.7B
Valuation
N/A
Accelerator
ACADIA Pharmaceuticals News
Acadia Pharmaceuticals Inc. ACAD-3.93%+ Free Alerts. announced topline results from a Phase 2 trial evaluating the efficacy and safety of...
By Stephen Nakrosis. Shares of Acadia Pharmaceuticals Inc. were lower in Monday's late-trading session, after the company said a Phase 2...
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, acquired CerSci Therapeutics, a clinical-stage biotechnology company with worldwide ...
ACADIA Pharmaceuticals, which is developing treatments for central nervous system and neurological disease, said this morning that it has received funding from Fast Forward LLC, a nonprofit established by the National Multiple Sclerosis Society, and EMD Serono, a subsidiary of Merck. ACADIA said ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35M | 690 | N/A | N/A |
#2 | $300M | 693 | -1% | $121M |
#3 | N/A | 698 | 10% | N/A |
#4 | $163.8M | 709 | N/A | N/A |
#5 | $142.5M | 712 | 1% | $238M |
ACADIA Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2003-03-31 | $25.0M | Private Placement | Oxford Bioscience Partners | Article |
| 2003-06-13 | $Undisclosed | Lead Investor: Oxfor | Article | |
| 2005-04-18 | $36.0M | Undisclosed | Article | |
| 2006-01-18 | $10.0M | Undisclosed | Sepracor Inc | Article |
| 2008-08-06 | $60.0M | Undisclosed | Kingsbridge Capital Limited | Article |
| 2011-01-11 | $15.0M | Undisclosed | JMP Securities LLC | Article |
| 2012-12-13 | $86.0M | Undisclosed | Jefferies & Company Inc, Cowen and Company LLC | Article |
| 2013-05-16 | $100.0M | Undisclosed | Jefferies LLC, Cowen and Company LLC | Article |
| 2014-03-05 | $182.4M | Undisclosed | Jefferies LLC | Article |
| 2016-01-06 | $Undisclosed | Undisclosed | BofA Merrill Lynch | Article |
| 2016-08-10 | $200.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2018-11-27 | $230.0M | Undisclosed | BofA Merrill Lynch, | Article |
| 2018-11-28 | $316.2M | Undisclosed | BofA Merrill Lynch, | Article |